JP2014511891A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511891A5
JP2014511891A5 JP2014505610A JP2014505610A JP2014511891A5 JP 2014511891 A5 JP2014511891 A5 JP 2014511891A5 JP 2014505610 A JP2014505610 A JP 2014505610A JP 2014505610 A JP2014505610 A JP 2014505610A JP 2014511891 A5 JP2014511891 A5 JP 2014511891A5
Authority
JP
Japan
Prior art keywords
compound
salt
methyl
pharmaceutically acceptable
acetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014505610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511891A (ja
JP5840763B2 (ja
Filing date
Publication date
Priority claimed from GB201106743A external-priority patent/GB201106743D0/en
Application filed filed Critical
Publication of JP2014511891A publication Critical patent/JP2014511891A/ja
Publication of JP2014511891A5 publication Critical patent/JP2014511891A5/ja
Application granted granted Critical
Publication of JP5840763B2 publication Critical patent/JP5840763B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014505610A 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 Expired - Fee Related JP5840763B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1106743.6 2011-04-21
GB201106743A GB201106743D0 (en) 2011-04-21 2011-04-21 Novel compounds
PCT/EP2012/057111 WO2012143413A1 (en) 2011-04-21 2012-04-19 Tetrahydroquinoline derivatives useful as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
JP2014511891A JP2014511891A (ja) 2014-05-19
JP2014511891A5 true JP2014511891A5 (https=) 2015-04-30
JP5840763B2 JP5840763B2 (ja) 2016-01-06

Family

ID=44147335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014505610A Expired - Fee Related JP5840763B2 (ja) 2011-04-21 2012-04-19 ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体

Country Status (16)

Country Link
US (1) US9029395B2 (https=)
EP (1) EP2699550B1 (https=)
JP (1) JP5840763B2 (https=)
KR (1) KR101896599B1 (https=)
CN (1) CN103619820B (https=)
AU (1) AU2012244759B2 (https=)
BR (1) BR112013026834A2 (https=)
CA (1) CA2832763C (https=)
EA (1) EA022341B1 (https=)
ES (1) ES2544302T3 (https=)
GB (1) GB201106743D0 (https=)
IL (1) IL228707A (https=)
MX (1) MX338515B (https=)
SG (1) SG194469A1 (https=)
WO (1) WO2012143413A1 (https=)
ZA (1) ZA201307645B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
NZ710765A (en) * 2013-03-14 2020-05-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
CA2915838C (en) 2013-06-21 2023-04-18 Zenith Epigenetics Corp. Bicyclic bromodomain inhibitors
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
AR096837A1 (es) 2013-07-08 2016-02-03 Incyte Corp Heterociclos tricíclicos como inhibidores de proteínas bet
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
EP3105232B1 (en) * 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituted triazolobenzodiazepines
EA034972B1 (ru) 2014-04-23 2020-04-13 Инсайт Корпорейшн 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet
RU2743074C2 (ru) 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
SG11201701043UA (en) 2014-09-12 2017-03-30 Glaxosmithkline Ip No 2 Ltd Tetrahydroquinoline derivatives as bromodomain inhibitors
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
AU2015326910B2 (en) * 2014-10-02 2018-03-01 Glaxosmithkline Intellectual Property (No.2) Limited Compound
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
EP3230277B1 (en) 2014-12-11 2019-09-18 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
KR102643344B1 (ko) 2016-06-20 2024-03-07 인사이트 코포레이션 Bet 저해제의 결정질 고체 형태
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
WO2018111805A1 (en) * 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Brd2ブロモドメイン結合剤
WO2009084693A1 (ja) 2007-12-28 2009-07-09 Mitsubishi Tanabe Pharma Corporation 抗癌剤
JP5572154B2 (ja) * 2009-03-31 2014-08-13 興和株式会社 テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
GB0919431D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011054851A1 (en) 2009-11-05 2011-05-12 Glaxosmithkline Llc Novel process
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201106750D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
WO2013033270A2 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same

Similar Documents

Publication Publication Date Title
JP2014511891A5 (https=)
JP2014511892A5 (https=)
JP2016503797A5 (https=)
JP2013537203A5 (https=)
JP2013519675A5 (https=)
JP2015505296A5 (https=)
JP2013510120A5 (https=)
JP2016530259A5 (https=)
JP2016515561A5 (https=)
JP2011529054A5 (https=)
JP2016506962A5 (https=)
JP2013508279A5 (https=)
JP2014521735A5 (https=)
JP2013543896A5 (https=)
JP2013542261A5 (https=)
JP2015501833A5 (https=)
JP2013509429A5 (https=)
JP2020532547A5 (https=)
RU2016134751A (ru) Соединения
JP2016531126A5 (https=)
JP2016506961A5 (https=)
JP2017504635A5 (https=)
JP2015522650A5 (https=)
JP2020502047A5 (https=)
JP2019501130A5 (https=)